Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
- Cicchiello F.
- Riva F.
- Cazzaniga M. E.
- Pedani F.
- Nicolini M.
- Butti C.
- Liscia N.
- Pogliani C.
- Capri G.
- Alu M.
- Febbraro A.
- Petrucelli L.
- D'Onofrio L.
- De Laurentiis M.
- Pellegrini D.
- Mentuccia L.
- Cocciolone V.
- Miraglio E.
- Bajardi E.
- Dester M.
- Paterno E.
- Guaitoli G.
- Ferrarini I.
- Gervasi E.
- Licata L.
- Benedetto C.
- Andreis D.
- Bordin E.
- Ancona C.
- Pizzuti L.
- Fotia V.
- Berardi R.
- Cazzaniga M. E.
- Airoldi M.
- Arcangeli V.
- Artale S.
- Atzori F.
- Ballerio A.
- Bianchi G. V.
- Blasi L.
- Campidoglio S.
- Ciccarese M.
- Cursano M. C.
- Piezzo M.
- Fabi A.
- Ferrari L.
- Ferzi A.
- Ficorella C.
- Frassoldati A.
- Fumagalli A.
- Garrone O.
- Gebbia V.
- Generali D.
- La Verde N.
- Maur M.
- Michelotti A.
- Moretti G.
- Musolino A.
- Palumbo R.
- Pistelli M.
- Porpiglia M.
- Sartori D.
- Scavelli C.
- Schirone A.
- Turletti A.
- Valerio M. R.
- Vici P.
- Zambelli A.
- Clivio L.
- Torri V.
DOIAbstract
Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Results From July 2013 to December 2015, the EVA study enrolled 4...
Add to ORKG